换一批
第一作者：
Guangdi,Li
第一单位：
Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha 410078, China.
作者：
关键词
3TC, (?)-2′,3′-dideoxy-3′-thiacytidine (common name, lamivudine)ABC, abacavirATV, atazanavirAZT, 3′-azido-3′-deoxy-thymidine (common name, zidovudine)BIC, bictegravirCAB, cabotegravirCC50, the 50 cytotoxic concentrationCOBI, cobicistatClinical efficacyDOR, doravirineDPV, dapivirineDRV, darunavirDTG, dolutegravirEACS, European AIDS Clinical SocietyEC50, half maximal effective concentrationEFV, efavirenzESV, elsulfavirineEVG, elvitegravirF, bioavailabilityFDA, US Food and Drug AdministrationFTC, (?)-2′,3′-dideoxy-5-fluoro-3′-thiacytidine (common name, emtricitabine)HAARTHAART, highly active antiretroviral therapyHIV treatmentHIV, human immunodeficiency virusIAS-USA, International Antiviral Society-USAIC50, half maximal inhibitory concentrationMSM, men who have sex with menNNRTINNRTI, non-nucleoside reverse transcriptase inhibitorNRTINRTI, nucleoside/nucleotide reverse transcriptase inhibitorRPV, rilpivirineTAF, tenofovir alafenamideTDF, tenofovir disoproxil fumaratet1/2, elimination half-life
DOI
10.1016/j.apsb.2021.11.009
PMID
35847492
发布时间
2023-09-01
- 浏览4
Acta pharmaceutica Sinica. B
2022年12卷4期
1567-1590页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
